healthcare costs
CTNJ OP-ED | Connecticut’s Healthcare Market Regulation is Broken
Connecticut’s healthcare markets are consolidating at a serious clip and it’s endangering access to care and driving up healthcare prices that make care unaffordable. Unfortunately, the state agency that is supposed to keep Connecticut’s healthcare market competitive isn’t acting. They have the tools – Connecticut has among the most protective laws in the nation. But…
Read MoreNew Cost Cap industry-driven committee gets going
Members of the Office of Health Strategy’s (OHS) latest committee to drive down the growth in Connecticut’s healthcare spending moved past their initial reluctance to engage in their November and December meetings. OHS expects the provider and insurer-dominated committee to agree on ways to reduce their own costs/profits. Hopefully, they do not also use the…
Read MoreFAQs on OHS’s Primary Care Roadmap
Download the FAQs here Connecticut’s Office of Health Strategy has developed a Primary Care Roadmap to support primary care in Connecticut. OHS is accepting public comment on the draft Roadmap until the close of business Friday, January 14th. To send comments, email Tina.Hyde@ct.gov and put “Primary Care Roadmap” in the subject line. You should get…
Read MorePublic comment concerns with CT’s primary care plan
Read the public comments Public comment concerns with CT’s primary care plan Today, the CT Health Policy Project submitted public comments with serious concerns about the Office of Health Strategy’s plans to overhaul primary care across the state. The Project has worked for decades to improve access to high quality, affordable care for every Connecticut…
Read MoreICER report on fair access to drugs prompts six insurers to change coverage policies
A powerful new scorecard from the Institute for Clinical and Economic Review (ICER) assessing 15 of the largest US formularies for barriers to accessing 28 fairly-priced drugs found generally good policies for clinical standards (96% are fair), step therapy (99%), and prescriber restrictions (100%). However, the report found poor policies for cost sharing tiers (77%)…
Read MoreOHS primary care committee sharply critical of agency’s plan
In this month’s meeting of the Office of Health Strategy’s Primary Care Subgroup, patient and consumer advocates joined insurers raising very strong concerns about OHS’s plans and capacity to implement the agency’s plan for primary care in Connecticut. OHS plans to double the share of Connecticut’s healthcare spending on primary care while tightly restricting growth…
Read MoreCTNJ Op-Ed – The Brainard Fund still making a difference after 64 years
In 2010, I got a call that advocates only dream about. The Hartford Foundation for Public Giving had a dedicated fund to pay medical bills for Hartford area residents who couldn’t afford them, and they wanted my help directing the money to people most in need. The good news is that the Brainard Fund still…
Read MoreLast year unjustified price increases for nine drugs cost US healthcare $1.67 billion, Humira accounted for $1.4 billion
According to this year’s report, last year the US health system spent an extra $1.67 billion on price increases for nine drugs that were not supported by clinical evidence. Humira led this year’s list at $1.4 billion, accounting for 84% of US unjustified drug price increases in 2020. Humira aside, the more modest price increases…
Read MoreResponse to OHS primary care capitation defense
Today, the CT Health Policy Project responded to a letter from the Office of Health Strategy regarding concerns from 25 independent consumer advocates, providers, and organizations. OHS’s response to our offer to work together to improve the health of every Connecticut resident is very welcome. In that spirit, the letter clarifies a few misunderstandings of…
Read MoreCTNJ op-ed: It’s a miracle — Under new agreement, Medicare will negotiate drug prices
Democrats in Washington have negotiated a deal to allow Medicare to negotiate prices with drug companies. Americans pay 2.56 times higher drug prices than residents of other developed countries. It has always been embarrassing that federal law prohibits Medicare drug price negotiation and the FDA can’t consider costs in drug approvals. The US is the…
Read More